Shore Capital Reiterates Buy Rating for hVIVO (LON:HVO)

hVIVO (LON:HVO)‘s stock had its “buy” rating reiterated by analysts at Shore Capital in a note issued to investors on Thursday,Digital Look reports. They presently have a GBX 25 price objective on the stock. Shore Capital’s price target indicates a potential upside of 308.50% from the company’s previous close.

Separately, Peel Hunt reaffirmed an “add” rating and issued a GBX 10 target price on shares of hVIVO in a research report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of GBX 17.50.

hVIVO Stock Up 2.0%

Shares of LON:HVO traded up GBX 0.12 during midday trading on Thursday, hitting GBX 6.12. 8,525,593 shares of the company’s stock traded hands, compared to its average volume of 2,780,105. The firm’s fifty day moving average price is GBX 5.97 and its two-hundred day moving average price is GBX 7.70. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. hVIVO has a twelve month low of GBX 4.31 and a twelve month high of GBX 20. The company has a market cap of £42.06 million, a PE ratio of 7.95 and a beta of 0.97.

Insider Activity at hVIVO

In related news, insider Stephen Pinkerton purchased 520,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was acquired at an average price of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan purchased 3,310,405 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was bought at an average price of GBX 6 per share, with a total value of £198,624.30. 4.43% of the stock is owned by insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.